Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 93

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 93
---
 and direct the negotiation of the terms and conditions of any potential transaction or other alternative, and authorize, monitor and
exercise general oversight on behalf of Enfusion of any and all agreements (including confidentiality and standstill agreements), proceedings and activities of Enfusion involving, responding to or relating to any potential transaction or other
alternative, (e) terminate any negotiations, discussions or consideration of, or reject, on behalf of Enfusion, any potential transaction or other alternative, (f) recommend to the Enfusion Board the advisability of entering into documents
and agreements with respect to any potential transaction or other alternative, (g) provide to the Enfusion Board a recommendation as to whether the Enfusion Board should approve or disapprove of any potential transaction or other alternative,
(h) monitor for, and take actions to resolve in accordance with the best interests of Enfusion and Enfusion Stockholders in their capacity as such, any developments or circumstances that would reasonably be expected to pose an actual or
potential conflict of interest affecting any director, officer, agent, employee or stockholder of Enfusion relative to a potential transaction or other alternative, a potential counterparty with respect to a potential transaction or other
alternative, and (i) engage the Special Committee’s own financial and legal advisors in connection with the foregoing. The Enfusion Board further resolved that the Enfusion Board would not approve a strategic transaction without a prior
favorable recommendation of such transaction by the Special Committee.

On August 16, 2024, the Special Committee held its
inaugural meeting with representatives of Goodwin and the General Counsel and Assistant General Counsel of Enfusion in attendance. The Special Committee interviewed law firms, including Dechert LLP (“”), to potentially serve
as outside counsel to the Special Committee.

On August 23, 2024, the Special Committee held a meeting with the General Counsel
and Assistant General Counsel of Enfusion in attendance. The Special Committee determined to select Dechert to serve as outside

59

counsel to the Special Committee based on Dechert’s expertise and other qualifications, including knowledge of the industry in which Enfusion operates and experience advising technology
companies and special committees in connection with the review and implementation of strategic alternatives, including strategic transactions.

On August 27, 2024, FTV confirmed that, at that time, FTV did not have an interest in acquiring Enfusion or have an intention to
proactively seek a rollover of their shares in a potential transaction and that FTV did not presently regard a rol